J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwartz, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwartz, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Race but not age affects erythromycin breath test results in older hypertensive men

JB Schwartz

Erythromycin breath tests (ERBT) were performed to determine age and racial effects on CYP3A4-mediated hepatic clearance in hypertensive men (n = 43) in the clinical setting. Older hypertensive African American men (n = 19: 71 +/- 8 years, mean +/- SD) had faster ERBT clearance compared with Caucasian (n = 20: 72 +/- 6 years) hypertensive men (at 20 minutes after dosing: 0.042 +/- 0.01 percent dose/min exhaled vs. 0.033 +/- 0.013; at 60 minutes after dosing: 0.030 +/- 0.05 vs. 0.023 +/- 0.007 percent dose/min exhaled; ANOVA, p = 0.007), while age, smoking, and reported alcohol intake did not affect ERBT. The data suggest faster hepatic CYP3A-mediated clearance in African American men compared with Caucasian men, and that race may significantly affect CYP3A-mediated hepatic clearance in patients treated for hypertension.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. Hurria, M. T. Fleming, S. D. Baker, Wm. K. Kelly, K. Cutchall, K. Panageas, J. Caravelli, H. Yeung, M. G. Kris, J. Gomez, et al.
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
Clin. Cancer Res., October 15, 2006; 12(20): 6100 - 6105.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
M. Gupta, A. Kovar, and B. Meibohm
The Clinical Pharmacokinetics of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction
J. Clin. Pharmacol., September 1, 2005; 45(9): 987 - 1003.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. ten Tije, J. Verweij, M. A. Carducci, W. Graveland, T. Rogers, T. Pronk, M.P. Verbruggen, F. Dawkins, and S. D. Baker
Prospective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the Elderly
J. Clin. Oncol., February 20, 2005; 23(6): 1070 - 1077.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. D. Baker, R. H. N. van Schaik, L. P. Rivory, A. J. ten Tije, K. Dinh, W. J. Graveland, P. W. Schenk, K. A. Charles, S. J. Clarke, M. A. Carducci, et al.
Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients
Clin. Cancer Res., December 15, 2004; 10(24): 8341 - 8350.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Pfister, L. Labbe, S. M. Hammer, J. Mellors, K. K. Bennett, S. Rosenkranz, and L. B. Sheiner
Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398
Antimicrob. Agents Chemother., January 1, 2003; 47(1): 130 - 137.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Clinical Pharmacology